Product1 publisher3 min readPublished
Pediatricians are putting 8-year-olds on GLP-1s four years below the label age
Semaglutide's approval starts above age 12 and tirzepatide's obesity approval at 18, but a published study and one Dallas hospital's own count both show children under 12 already taking these drugs, mostly for obesity and type 2 diabetes.
The Product Desk · Product desk
What happened
- A study published last week found 0.6% of children aged 8 to 11 with obesity and no diabetes had been prescribed an off-label GLP-1 between 2019 and 2026, with the annual share climbing each year.
- Semaglutide, sold as Ozempic and Wegovy, is approved only for children over 12, and Novo Nordisk is seeking approval for younger age groups.
- Tirzepatide is approved as an obesity treatment only for people over 18, though it is cleared for children with diabetes from age 10.
- Novo Nordisk presented trial data this week showing 40% of children aged six to 12 were no longer considered obese after 68 weeks of treatment.
- The American Academy of Pediatrics began recommending a more proactive approach to childhood obesity, GLP-1 drugs included, in 2023.
Compiled by The Product DeskSomething wrong?How this is made
Why it matters
- contradiction The two authorities point opposite ways: the pediatric academy endorses these drugs for children while the U.S. Preventive Services Task Force has withheld a recommendation for lack of data. Whoever writes a coverage or eligibility rule picks one of them, and defends that citation in review.
- decision An age gate copied from the label refuses the 8-to-11 band that clinicians are already treating, so the design choice is whether a refusal is final or routes to a human who can be named in the chart note.
- precedent Children who do not respond to the first drug are being moved onto one whose obesity approval sits at 18. That ordering puts the least-approved option at the end of the care pathway, and the coverage argument gets harder the longer a child stays in treatment.
- constraint For anyone designing monitoring, refill or follow-up flows for an eight-year-old, the trial evidence stops at week 68. The follow-up schedule is a judgement call made by the product team and the prescriber.
Sarah Messiah, an epidemiologist and childhood obesity researcher at the University of Texas Southwestern Medical Center, described the decision that puts a child on one of these drugs before the label allows it [8]. Her guess, she said, is that these are children with a strong family history and predisposition for obesity or type 2 diabetes, or ones where things are progressing more aggressively, and their pediatricians are saying "Okay, we want to try a GLP-1 off-label earlier" [19]. "And across all these recent studies, you can clearly see that pediatricians are already going down this road, because they're thinking they've got to try things that hopefully work," Messiah said [12].
Her local numbers are not published. She said she ran the under-12 breakdown after Gizmodo emailed her, using prescribing data from Children's Health in Dallas covering 2020 to last month [16]. Almost 2,000 children there have been given a GLP-1 or a GIP since 2020, and 7% of them were age 11 or below, mostly prescribed for obesity and type 2 diabetes [9][10]. Seven percent of nearly 2,000 is about 140 children in one hospital system [11].
That 7% measures something different from the 0.6% in the published study. Messiah's figure divides under-12s by everyone her clinic has treated up to age 21 [10]. The study's divides prescriptions by all 8-to-11-year-olds who have obesity and no diabetes, a denominator that includes every child who never saw a prescriber [1].
Who is in that cohort matters to whoever ends up paying for it. Messiah said Children's Health is a safety net hospital where 64% of patients are on Medicaid [14]. "This isn't just, I don't want to say, a bunch of rich kids, but it's not that," she said [15].
The pathway also escalates. Messiah said doctors are starting to place pediatric patients on drugs like tirzepatide, "probably because they're not responding to earlier drugs" [13]. Semaglutide's pediatric approval starts above age 12; tirzepatide's obesity approval starts at 18 [6][7]. An eight-year-old on semaglutide is four years under the first line and ten under the second [18].
For anyone maintaining eligibility logic, one split is between rules keyed to the label and rules keyed to a clinician's note. Cross that with whether a denial can be reversed in one step or has to be argued by phone. The 0.6% sizes an exception; the 7% sizes a standing part of a specialty clinic's caseload [1][10]. A system built on the label alone will refuse most of the under-12 group Messiah counted, and that refusal reaches a prescriber who has already made the call [6][10]. CDC data put 21% of children aged 6 to 11 and 22% of adolescents aged 12 to 19 in the obese category [2], and bariatric surgery is only recommended from age 13 [17].
What to watch
- Whether the FDA grants Novo Nordisk's pending application to extend semaglutide approval to children under 12. That approval would move this group inside the label.
- Whether Messiah publishes the Dallas under-12 sub-analysis with a denominator other researchers can check.
- Whether Medicaid coverage decisions follow the pediatric academy's guidance for under-12s, given how much of this prescribing sits in a safety net population.